Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (DE:GIS)
XETRA:GIS
Holding DE:GIS?
Track your performance easily
GIS Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€57.29 - €92.80
Previous Close€89.17
Volume545.00
Average Volume (3M)2.12K
Market Cap
€111.87B
Enterprise Value€134.13B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$23.25B
Price to Earnings (P/E)990.8
Beta0.20
Next Earnings
Feb 11, 2025EPS Estimate
€1.65Last Dividend Ex-Date
Dec 13, 2024Dividend Yield3.28%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,246,265,857
10 Day Avg. Volume1,474
30 Day Avg. Volume2,117
Standard Deviation0.07
R-Squared0.00029
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)6.02
Price to Sales (P/S)4.11
Price to Cash Flow (P/CF)6.80
P/FCF Ratio7.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.74
Enterprise Value/Gross Profit6.51
Enterprise Value/Ebitda38.95
Forecast
1Y Price Target
€94.28Price Target Upside5.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
HIV Treatment InnovationGilead Sciences is anticipated to see growth in the HIV treatment market, with the potential for continued expansion and new treatment regimens.
Lenacapavir Launch StrategyLenacapavir's launch in the PrEP market is targeting rapid access, with expectations of high physician and patient demand and broad coverage.
Market Diversification And GrowthThe introduction of new long-acting HIV treatments is anticipated to replace a significant portion of Biktarvy revenues, offering potential upside for Gilead Sciences' shares.
Bears Say
Competitive Pressure In Cell TherapyThe cell therapy business faced competitive pressure with combined sales of Yescarta/Tecartus incrementally underperforming estimates.
Diversification ChallengesThe path to diversification outside virology has been challenging and the missteps so far have been keeping some investors on the sidelines.
Trodelvy Approval WithdrawalThe decision to withdraw Trodelvy from U.S. accelerated approval in 2LmUC adds to the challenges faced by Gilead's solid-tumor franchise.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
30.06% Mutual Funds
23.21% Other Institutional Investors
20.40% Public Companies and
Individual Investors
GIS FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was €57.29 and its highest was €92.80 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Feb 11, 2025 which is in 47 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Nov 06, 2024. The company reported €1.941 earnings per share for the quarter, beating the consensus estimate of €1.47 by €0.471.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of €0.739 which represents an annual dividend yield of 3.28%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is €1.65.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,265,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of €1.941 in its last earnings report, beating expectations of €1.47. Following the earnings report the stock price went up 5.427%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 3B.
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€94.28 (5.73% Upside)
€94.28 (5.73% Upside)
Blogger Sentiment
Bullish
DE:GIS Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $15.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.75%
12-Months-Change
Fundamentals
Return on Equity
0.62%
Trailing 12-Months
Asset Growth
-12.58%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
GIS Company Deck
---
GIS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth across key segments like HIV and oncology. The company showed progress in its pipeline with promising drug candidates and improved financial guidance for 2024. However, there were challenges in the cell therapy segment and a significant impairment charge impacting financial results.Read More>---
GIS Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
GIS Stock 12 Month Forecast
Average Price Target
€94.28
▲(5.73% Upside)
Technical Analysis
Best Analysts Covering GIS
1 Year
1 Year Success Rate
18/27 ratings generated profit
1 Year Average Return
+12.20%
reiterated a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +12.20% per trade.
---